Head to Head Analysis: Pheton (NASDAQ:PTHL) versus BioNexus Gene Lab (NASDAQ:BGLC)

Pheton (NASDAQ:PTHL) and BioNexus Gene Lab (NASDAQ:BGLC) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership and earnings.

Institutional & Insider Ownership

18.9% of BioNexus Gene Lab shares are owned by institutional investors. 0.1% of BioNexus Gene Lab shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Pheton and BioNexus Gene Lab’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pheton	N/A	N/A	N/A
BioNexus Gene Lab	-54.70%	-37.43%	-32.88%

Earnings & Valuation

This table compares Pheton and BioNexus Gene Lab”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pheton	$305,215.00	6.60	-$660,000.00	N/A	N/A
BioNexus Gene Lab	$7.43 million	0.66	-$2.98 million	($1.48)	-1.38

Pheton has higher earnings, but lower revenue than BioNexus Gene Lab.

Risk & Volatility

Pheton has a beta of 5.4, meaning that its share price is 440% more volatile than the S&P 500. Comparatively, BioNexus Gene Lab has a beta of 4.06, meaning that its share price is 306% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Pheton and BioNexus Gene Lab, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pheton	1	0	0	0	1.00
BioNexus Gene Lab	1	0	0	0	1.00

Summary

Pheton beats BioNexus Gene Lab on 6 of the 9 factors compared between the two stocks.

About Pheton

Pheton Holdings Ltd. operates as a holding company with interests in providing healthcare solutions. The firm through its subsidiaries engages in the development and commercialization of brachytherapy TPS specifically used for radioactive particle implantation, a type of radiotherapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. The company was founded in 1998 and is headquartered in Beijing, China.

About BioNexus Gene Lab

BioNexus Gene Lab Corp., through its subsidiary, sells chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company offers chemical raw material products, which include Polyester Resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; Polyester Resin 9509, a general-purpose material used in production of marine boats and water slides; and Polyester Resin 2802 used as a component in the pultrusion process by certain manufacturers. Its products are used to produce handrails, bench tops, automotive and aero parts, and paneling for hospital, laboratory, industrial clean rooms, and covers for various instruments used in manufacturing. The company also involves in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers to detect potential risk of diseases. It markets its products through its website, warehouse, marketing personnel, and suppliers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.